Member Info for marik

Have at look at Myles comment:

"I’m more confident than ever - especially after the weekend’s press re: LFT usage over isolation that #AVCT’s AffiDX is going to sell in colossal quantities over the next 1-2 years.

Heavy lifting done: it’s a matter of sitting on hands, ignoring the detractors - the shorts, the impatient and the trolls - and waiting for that multi-billion £ market cap."

You've got the wrong type of sales. If there is a new distribution agreement is made, then it's a requirement on Avacta to RNS that specific agreement. How many sales are they will get at "XX million" a month is usually not part of that news. Have a look across the numerous companies on various stock exchanges across the world and you will find that the Avacta RNS is in keeping.

You are very impatient, it really speaks volumes of your lack of experience.

As Myles put it, the aim is to have "20+ other distribution partners like Calibre". This would make Avacta a household name across the world.

Distribution in the UK and EEA is a major deal along with APAC (with half the world's population!). Avacta are about to make some serious inroads.

https://www.yorkshirepost.co.uk/business/avacta-signs-up-major-us-partner-for-its-covid-19-tests-3280316

cider, it's best not to get impatient, it smacks of day trading/shorting. The sales are inevitable, why have a meltdown at this stage. Instead of moaning, you have another option - sell and let the rest of us add.

GL

Another great tweet by Myles:

https://twitter.com/MylesMcNulty/status/1406869467561398275

Makes no difference about tomorrow, as it will go up substantially in the near future.

It should be a good presentation. I'm expecting some, but not a huge amount of detail of the list two to three months. However, I am expecting an RNS over the coming few weeks.

Has anyone else on this board received one? Or perhaps likely to get one?

Thanks for sharing sledgey121, this is major news.

Thank you for sharing scardey_cat. This implies that Innova are still under review. It also suggests that the data that the MHRA had available wasn't sufficient, something that experts have been calling for a long time. That's including Professor Jon Deeks.

Innova are therefore under scrutiny over the next two months and will not be exempt as many have assumed. Innova won't pass the "test to release" standards and will be dropped. This was also evident from the comments made by Professor Sheila Bird amongst others.

The UK market is indeed very wide open.

Thanks for sharing scardey_cat and also sledgey121 over at the "other" board.

GLA

You're such an eggspert.

It's Avacta all the way from here.

That's the point. They won't be given green light status *ever* with their current test.

Innova won't be exempted or extended beyond the two months. As I've said before, MHRA Buying Time to Investigate Innova:

https://www.lse.co.uk/ShareChat.asp?ShareTicker=AVCT&share=Avacta&thread=5D495A04-3897-44AA-BC4E-5DB89C963E8F

Innova is test to isolate.

Avacta?

I'm glad the penny is starting to drop.

The Test & Release was referenced quite a few times in the article by Sheila Bird yesterday, which I commented on in an earlier post.

https://www.lse.co.uk/ShareChat.asp?ShareTicker=AVCT&share=Avacta&thread=5D495A04-3897-44AA-BC4E-5DB89C963E8F

Indeed. Test & Release is the new phrase and Innova is not fit for test and release.